Clinical & Experimental Cardiology
Open Access
ISSN: 2155-9880
+44 1300 500008
ISSN: 2155-9880
+44 1300 500008
Wilbert S Aronow
Cardiology Division, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY 10595,
Tanzania
Review Article
Treatment of Hypercholesterolemia
Author(s): Wilbert S AronowWilbert S Aronow
Numerous randomized, double blind, placebo-controlled studies and observational studies have shown that statins reduce mortality and major cardiovascular events in high-risk patients with hypercholesterolemia. The Heart Protection Study showed that statins reduced mortality and major cardiovascular events in high-risk patients regardless of the initial level of serum lipids, age, or gender. The updated National Cholesterol Education program III guidelines state that in very high-risk persons, a serum low-density lipoprotein (LDL) cholesterol level of <70 mg/L is a reasonable clinical strategy. For moderately high-risk persons ( 2 or more risk factors and a 10-year risk for coronary artery disease of 10% to 20%), the serum LDL cholesterol should be reduced to <100 mg/dL. When LDL cholesterol-lowering drug therapy is used to treat high-risk persons or moderately high-risk persons,.. View More»
DOI:
10.4172/2155-9880.S1-006